Elite Pharmaceuticals, Inc.

Total Valuation

Elite Pharmaceuticals, Inc. carries a market capitalization of 280.07M, placing it among publicly traded companies globally. Its enterprise value stands at 359.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Elite Pharmaceuticals, Inc. currently has 1.08B shares outstanding.

Valuation Ratios

Elite Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 66.37. The price-to-sales ratio is 2.78, and the price-to-book ratio stands at 3.75.

Enterprise Valuation

On an enterprise value basis, Elite Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 9.52 and an EV/FCF ratio of 17.28. The EV/Sales ratio of 2.55 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.06 provides insight into valuation relative to core operating earnings.

Financial Position

Elite Pharmaceuticals, Inc. maintains a current ratio of 3.76, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.32, indicating elevated leverage, while an interest coverage ratio of 121.58 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Elite Pharmaceuticals, Inc. posts a return on equity of 7.75 and a return on invested capital of 37.84.

Taxes

Over the trailing twelve months, Elite Pharmaceuticals, Inc. has paid 8.43M in income taxes, reflecting an effective tax rate of 12.95.

Stock Price Statistics

Elite Pharmaceuticals, Inc.'s stock has declined approximately -62.50793% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 0.40.

Income Statement

Over the trailing twelve months, Elite Pharmaceuticals, Inc. generated 141.01M in revenue and converted that into 5.91M in net income, yielding earnings per share of 0.05. EBITDA reached 37.79M, while operating income came in at 35.79M.

Balance Sheet

Elite Pharmaceuticals, Inc. holds 38.94M in cash and equivalents against 5.57M in total debt, resulting in a net debt position of -35.93M. Total book value stands at 104.83M, with working capital of 84.05M providing operational flexibility.

Cash Flow

Elite Pharmaceuticals, Inc. produced 19.04M in operating cash flow over the past twelve months. After subtracting -1.52M in capital expenditures, free cash flow totaled 17.53M - equivalent to 0.02 per share.

Margins

Elite Pharmaceuticals, Inc. operates with a gross margin of 43.47, reflecting its pricing power and cost economics. The operating margin of 25.38 and net profit margin of 4.19 provide insight into operational efficiency.

Dividends & Yields

Scores

Elite Pharmaceuticals, Inc. posts an Altman Z-Score of 8.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.